Clinical Trials on Hemophilia B

Total 6604 results

Jiangsu Gensciences lnc.

Completed

A Study to Evaluate the Pharmacokinetics，Safety and Tolerability of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
Jiangsu Gensciences lnc.

Completed

A Study of Repeat Dosing of PEG Recombinant Human Coagulation Factor VIII-Fc Fusion Protein for Injection

Severe Hemophilia A

China
CSL Behring

Completed

An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Hemophilia A | Severe Hemophilia A

United States, Australia, Austria, Canada, Czechia, France, Georgia, Germany, Hungary, Ireland, Italy, Japan, Lebanon, Malaysia, Netherlands, Philippines, Poland, Portugal, Romania, South Africa, Spain, Switzerland, Thailand, Ukraine, United...
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Withdrawn

Study of First TIME Immunotolerance Induction in Severe Hemophilia A Patients With Inhibitor at High Risk of Failure: Comparison With FVIII Concentrates With or Without Von Willebrand Factor - RES.I.S.T. Naive (RESIST NAIVE)

Severe Hemophilia A
Oslo University Hospital
Norwegian School of Sport Sciences

Completed

HemFitBit, an Observational Study of Physical Activity in People With Moderate and Severe Haemophilia A

Hemophilia A Without Inhibitor

Norway
University of California, Davis

Terminated

INdividualized ITI Based on Fviii(ATE) Protection by VWF (INITIATE)

Hemophilia A | Hemophilia A With Inhibitor

United States
The Hospital for Sick Children

Completed

Canadian Hemophilia Prophylaxis Study (CHPS)

Severe Hemophilia A

Canada
Octapharma

Completed

Efficacy and Safety Study of Human-cl rhFVIII in PTPs With Severe Hemophilia A

Severe Hemophilia A

Germany, Austria, United Kingdom, Bulgaria
CSL Behring

Completed

Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A

Congenital Hemophilia A

United States, Austria, Germany, Malaysia, Netherlands, Philippines, Ukraine, Romania, Spain, Australia, France, Georgia, Italy, Lebanon, Poland, Portugal, Switzerland, Thailand, Turkey
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...

Unknown

rFVIIa Prophylaxis in Children With Hemophilia A and Inhibitors (ENJOIH)

Hemophilia A With Inhibitors

United States, Germany, France, Italy, Romania, Spain
Hoffmann-La Roche

Completed

An Observational Study to Evaluate Physical Activity, Bleeding Incidence and Health Related Quality of Life, in Participants With Haemophilia A Without Inhibitors Receiving Standard of Care Treatment (POWER)

Haemophilia A | Moderate Hereditary Factor VIII Deficiency Disease Without Inhibitor | Severe Hereditary Factor VIII Deficiency Disease Without Inhibitor

Italy
Jiangsu Gensciences lnc.

Recruiting

Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein

Severe Hemophilia A

China
Octapharma

Recruiting

Nuwiq for Perioperative Management Of Patients With Haemophilia A on Emicizumab Regular Prophylaxis Study (NuPOWER)

Severe Hemophilia A

Spain, Croatia, Italy, North Macedonia, Serbia
Institute of Hematology & Blood Diseases Hospital...
Sinocelltech Ltd.

Recruiting

ITI Using SCT800 Alone or Combining Daratumumab in Hemophilia A Adolescents and Adults With High Titer Inhibitor

Hemophilia A With Inhibitor

China
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Eradication Trial

Hemophilia A With Inhibitor

United States
Octapharma

Terminated

Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria
Children's Hospital Los Angeles
Takeda

Active, not recruiting

A Study to Evaluate the Safest Dose Range for FEIBA in Hemophilia A Patients With Inhibitors on Emicizumab

Hemophilia A With Inhibitor

United States
City of Hope Medical Center
CSL Behring; Grifols Therapeutics LLC; Grifols Biologicals, LLC; Charta Foundation and other collaborators

Completed

Rescue Immunotolerance Study in Induction of Immune Tolerance (ITI)-Experienced Patients (RES.I.S.T. Experienced) (RESIST EXP)

Severe Hemophilia A

United States
Octapharma

Completed

Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Wilate in Previously Treated Paediatric Patients With Severe Haemophilia A

Severe Hemophilia A

Russian Federation, Ukraine
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Octapharma

Completed

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

Severe Hemophilia A

United States, Bulgaria
Margaret Ragni

Withdrawn

Hemophilia Inhibitor Clinical Trials (INHIBIT) Platform (INHIBIT)

Severe Hemophilia A

United States
Beijing Children's Hospital

Unknown

Low-dose ITI Strategy for Children in Hemophilia A With High-titer Inhibitor and Poor ITI Risk in China (HA-LD-ITI)

Hemophilia A With Inhibitor

China
Skane University Hospital

Completed

The Malmö International Brother Study (MIBS)

Hemophilia A With Inhibitors

Sweden
Tri-Service General Hospital

Recruiting

A Study on the Bone-health Effectiveness of Applying Recombinant Factor VIII Fc (rFVIIIFc) to Patients With Hemophilia A (Prototype A)

Severe Hemophilia A Without Inhibitor

Taiwan
Groupe Maladies hémorragiques de Bretagne

Recruiting

Genetic Influence of Genetic Factors Influencing the Desmopressin's Efficacy in Mild/Moderate Hemophilia A (GIDEMHA)

Desmopressin | Hemophilia A, Mild | Factor VIII

France
Chulalongkorn University

Completed

Clinical Outcomes of Low Dose PK-guided EHL FVIII Concentrates Versus Standard Prophylaxis in Severe Haemophilia A

Severe Hemophilia A Without Inhibitor

Thailand
Skane University Hospital

Completed

The FEIBA NovoSeven Comparative Study

Severe Hemophilia A With an Inhibitor

Sweden
Enzyre B.V.
Instytut Hematologii i Transfuzjologii, Warschau, Poland

Completed

Real-life Clinical FEIBA Samples Measured Using the Version A of the HemA EnzySystem

Hemophilia A | Hemophilia A With Inhibitor

Poland
Hoffmann-La Roche

Active, not recruiting

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors (HAVEN 7)

Severe Hemophilia A

Canada, United States, United Kingdom, Belgium, Australia, Austria, Brazil, France, Germany, Israel, Italy, South Africa, Spain, Turkey
Swedish Orphan Biovitrum
Cerner Enviza

Completed

rFVIIIFc (Elocta®) ITI Chart Review in Patients With Haemophilia A

Hemophilia A With Inhibitor

France, Ireland, Italy, Norway, Germany, Kuwait, Saudi Arabia, Switzerland
AryoGen Pharmed Co.

Completed

rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study

Severe Hemophilia A

Iran, Islamic Republic of
Bayer

Completed

Study Evaluating "Real World" Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog Alfa) for Routine Prophylaxis (TAURUS)

Hemophilia A, Congenital

Slovenia, Italy, Germany, France, United States, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Taiwan
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Prevention Trial

Hemophilia A Without Inhibitor

United States
Grifols Biologicals, LLC

Completed

Safety Study of Alphanate in Previously Treated Patients With Severe Hemophilia A

Severe Hemophilia A

Poland
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
Grifols Therapeutics LLC
Grifols Biologicals, LLC

Terminated

Alphanate in Immune Tolerance Induction Therapy

Hemophilia A, Congenital

United States, Spain, Italy, India, Canada, Russian Federation
Octapharma

Completed

Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients

Severe Hemophilia A

Canada, United States, France, Spain, Ukraine, United Kingdom, Belarus, Georgia, Germany, India, Italy, Moldova, Republic of, Morocco, Poland, Portugal, Russian Federation, Slovenia
Octapharma

Completed

Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A

Severe Hemophilia A

Bulgaria, Poland, Hungary, Romania, Russian Federation
Bioverativ Therapeutics Inc.

Completed

Study of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, Hong Kong, Israel
Children's Hospital Los Angeles

Withdrawn

Individualizing Hemophilia Bypassing Agent Therapy Utilizing Thromboelastography

Hemophilia A With Inhibitors
University of Pittsburgh
National Heart, Lung, and Blood Institute (NHLBI)

Terminated

Hemophilia Adult Prophylaxis Study: Factor VIII in Severe Hemophilia A

Severe Hemophilia A

United States
Nara Medical University
Shire

Unknown

Basic Study of Combination Therapy Based on APCC-induced FVllI Activation in Hemophilia A Patients With Inhibitors

Hemophilia A With Inhibitor

Japan
Skane University Hospital

Completed

Hemophilia Inhibitor Genetics Study (HIGS)

Hemophilia A With Inhibitor

Sweden
New York Presbyterian Hospital
Manchester University NHS Foundation Trust

Terminated

International Immune Tolerance Study

Hemophilia A With Inhibitors

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

National Longitudinal Cohort of Hematological Diseases (NICHE)

Lymphoma | Acute Myeloid Leukemia | Leukemia | Hemophilia A | Hemophilia B | Hemophilia | Multiple Myeloma | Myelodysplastic Syndrome | Bone Marrow Transplantation | MDS | Aplastic Anemia | Bleeding Disorder | Myeloma, Multiple | Myelomas, Multiple | Leukemias, Acute Myeloid | Myeloid Leukemias, Acute | Hemophilia As | Hemophilia... and other conditions

China
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

Severe Hemophilia A

United States, United Kingdom, Spain, Hong Kong, Israel, New Zealand, Sweden, Australia, Brazil, Japan, Austria, Belgium, Italy, India, Switzerland, Canada, France, Germany, South Africa
Tsung-Ying Li

Recruiting

Vitamin D Deficiency and Body Composition in the Patients With Hemophilia

Hemophilia | Vitamin D Deficiency | Body Composition | Sarcopenia | Osteoporosis | Hemophilic Arthropathy

Taiwan

Clinical Trials on Hemophilia B

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations